WallStreetZenWallStreetZen

NASDAQ: BVS
Bioventus Inc Stock Forecast, Predictions & Price Target

Analyst price target for BVS

Based on 2 analysts offering 12 month price targets for Bioventus Inc.
Min Forecast
$7.00+68.67%
Avg Forecast
$8.00+92.77%
Max Forecast
$9.00+116.87%

Should I buy or sell BVS stock?

Based on 2 analysts offering ratings for Bioventus Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BVS stock forecasts and price targets.

BVS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-13
lockedlocked$00.00+00.00%2023-12-07

1 of 1

Forecast return on equity

Is BVS forecast to generate an efficient return?
Company
N/A
Industry
-0.02%
Market
19.57%

Forecast return on assets

Is BVS forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.02%

BVS revenue forecast

What is BVS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$529.1M+3.27%
Avg 2 year Forecast
$559.3M+9.16%
Avg 3 year Forecast
$588.4M+14.84%
BVS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BVS revenue growth forecast

How is BVS forecast to perform vs Medical Devices companies and vs the US market?
Company
4.45%
Industry
8.61%
Market
9.23%
BVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BVS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BVS vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
BVS$4.15$8.00+92.77%Strong Buy
VMD$8.09N/AN/A
TCMD$15.04N/AN/A
CVRX$14.40$33.67+133.80%Strong Buy
CERS$1.66$2.75+65.66%Buy

Bioventus Stock Forecast FAQ

Is Bioventus Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BVS) stock is to Strong Buy BVS stock.

Out of 2 analysts, 1 (50%) are recommending BVS as a Strong Buy, 1 (50%) are recommending BVS as a Buy, 0 (0%) are recommending BVS as a Hold, 0 (0%) are recommending BVS as a Sell, and 0 (0%) are recommending BVS as a Strong Sell.

If you're new to stock investing, here's how to buy Bioventus stock.

What is BVS's revenue growth forecast for 2024-2026?

(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 4.45% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.

Bioventus's revenue in 2024 is $512,345,000.On average, 1 Wall Street analysts forecast BVS's revenue for 2024 to be $41,884,903,903, with the lowest BVS revenue forecast at $41,884,903,903, and the highest BVS revenue forecast at $41,884,903,903. On average, 1 Wall Street analysts forecast BVS's revenue for 2025 to be $44,277,286,522, with the lowest BVS revenue forecast at $44,277,286,522, and the highest BVS revenue forecast at $44,277,286,522.

In 2026, BVS is forecast to generate $46,578,628,770 in revenue, with the lowest revenue forecast at $46,578,628,770 and the highest revenue forecast at $46,578,628,770.

What is BVS's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: BVS) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of -0.02%.

What is BVS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BVS price target, the average BVS price target is $8.00, with the highest BVS stock price forecast at $9.00 and the lowest BVS stock price forecast at $7.00.

On average, Wall Street analysts predict that Bioventus's share price could reach $8.00 by Mar 13, 2025. The average Bioventus stock price prediction forecasts a potential upside of 92.77% from the current BVS share price of $4.15.

What is BVS's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: BVS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.